The FINANCIAL — Takeda Pharmaceutical Company Limited announced that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW). Moderna has previously announced that the 30,000 participant Phase 3 clinical trial of mRNA-1273 at the 100 µg dose level in the U.S. is fully enrolled. This follows Takeda’s recent announcement that it is establishing the capability to manufacture Novavax’ COVID‑19 vaccine candidate…
Read More »
The FINANCIAL — Takeda Pharmaceutical Company Limited announced that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and…
You might be interested in
Older people are likely to be vaccinated regardless of party affiliation. New research from the University of Georgia suggests age and…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…
In the UK, there were 346 deaths involving COVID-19 registered in the week ending 24 June 2022, an increase from…